These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 18382212

  • 1. Advances in the treatment of heart failure with a preserved ejection fraction.
    Das A, Abraham S, Deswal A.
    Curr Opin Cardiol; 2008 May; 23(3):233-40. PubMed ID: 18382212
    [Abstract] [Full Text] [Related]

  • 2. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
    Meune C, Wahbi K, Duboc D, Weber S.
    J Cardiovasc Pharmacol Ther; 2011 May; 16(3-4):368-75. PubMed ID: 21193681
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, SENIORS Investigators.
    J Am Coll Cardiol; 2009 Jun 09; 53(23):2150-8. PubMed ID: 19497441
    [Abstract] [Full Text] [Related]

  • 5. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
    Shah RV, Desai AS, Givertz MM.
    J Card Fail; 2010 Mar 09; 16(3):260-7. PubMed ID: 20206902
    [Abstract] [Full Text] [Related]

  • 6. Treatment of heart failure with preserved systolic function.
    de Groote P, Herpin D, Diévart F, Hanon O, Trochu JN, Artigou JY, Galinier M, Habib G, Juillière Y, Neuder Y, Roudaut R, Komajda M.
    Arch Cardiovasc Dis; 2008 May 09; 101(5):361-72. PubMed ID: 18656095
    [Abstract] [Full Text] [Related]

  • 7. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
    Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Hospitals.
    J Am Coll Cardiol; 2007 Aug 21; 50(8):768-77. PubMed ID: 17707182
    [Abstract] [Full Text] [Related]

  • 8. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
    Dulin BR, Krum H.
    Curr Opin Cardiol; 2006 Jul 21; 21(4):393-9. PubMed ID: 16755210
    [Abstract] [Full Text] [Related]

  • 9. The HF epidemic: the need for new treatment strategies.
    Carson PE.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 21; 1(2 Suppl):S32-4. PubMed ID: 17199218
    [Abstract] [Full Text] [Related]

  • 10. Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER study (Identification of Patients With Heart Failure and PREserved Systolic Function: an epidemiological regional study).
    Magaña-Serrano JA, Almahmeed W, Gomez E, Al-Shamiri M, Adgar D, Sosner P, Herpin D, I PREFER Investigators.
    Am J Cardiol; 2011 Nov 01; 108(9):1289-96. PubMed ID: 22000627
    [Abstract] [Full Text] [Related]

  • 11. The cellular and physiologic effects of beta blockers in heart failure.
    Sabbah HN.
    Clin Cardiol; 1999 Oct 01; 22 Suppl 5():V16-20. PubMed ID: 10526699
    [Abstract] [Full Text] [Related]

  • 12. Experience with beta blockers in heart failure mortality trials.
    Eichhorn EJ.
    Clin Cardiol; 1999 Oct 01; 22 Suppl 5():V21-9. PubMed ID: 10526700
    [Abstract] [Full Text] [Related]

  • 13. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
    Mariotti R, Borelli G, Coceani M, Zingaro S, Barison A, Morelli I, Rondinini L.
    J Clin Pharm Ther; 2008 Aug 01; 33(4):349-56. PubMed ID: 18613852
    [Abstract] [Full Text] [Related]

  • 14. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 01; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 15. Outcomes in patients with heart failure with preserved ejection fraction.
    Poppe KK, Doughty RN.
    Heart Fail Clin; 2014 Jul 01; 10(3):503-10. PubMed ID: 24975912
    [Abstract] [Full Text] [Related]

  • 16. Heart failure: is there a role for angiotensin II receptor blockers?
    Boucher M, Ma J.
    Issues Emerg Health Technol; 2002 Sep 01; (38):1-4. PubMed ID: 12243202
    [Abstract] [Full Text] [Related]

  • 17. Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction.
    Agarwal V, Briasoulis A, Messerli FH.
    Heart Fail Rev; 2013 Jul 01; 18(4):429-37. PubMed ID: 22678768
    [Abstract] [Full Text] [Related]

  • 18. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
    Dhaliwal AS, Bredikis A, Habib G, Carabello BA, Ramasubbu K, Bozkurt B.
    Am J Cardiol; 2008 Nov 15; 102(10):1356-60. PubMed ID: 18993155
    [Abstract] [Full Text] [Related]

  • 19. Comparison of morbidity in women versus men with heart failure and preserved ejection fraction.
    Deswal A, Bozkurt B.
    Am J Cardiol; 2006 Apr 15; 97(8):1228-31. PubMed ID: 16616031
    [Abstract] [Full Text] [Related]

  • 20. Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction.
    Tehrani F, Phan A, Chien CV, Morrissey RP, Rafique AM, Schwarz ER.
    Am J Cardiol; 2009 Mar 15; 103(6):829-33. PubMed ID: 19268740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.